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Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by clinical and
molecular features, including targetable mutations in several kinases. The successful development of therapies,
targeting mutated BRAF (v-raf murine sarcoma viral oncogene homolog B1) or c-KIT (v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog), has resulted in new treatment options including vemurafenib, imatinib and mitogen-
activated protein kinase inhibitors. These molecules are selected if the respective mutation is present. After this ﬁrst
progress in the treatment of advanced melanoma, there is expectation that combinations of kinase inhibitor will
additionally improve the overall survival rates and progression-free survival in advanced melanoma.
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introduction
Melanoma is the most common lethal cutaneous malignancy.
It is derived from melanocytes originating from the neural
crest. The genetic events and their relationship to the
complex interaction with the microenvironment transforming
normal melanocytes into melanoma are under intensive
investigation.
retrospective view of chemotherapy
For decades chemotherapy was the backbone of systemic
treatment in cases of distant metastasis. Dacarbacine (DTIC) is
still the most used cytotoxic agent in metastatic melanoma and
remains the standard ﬁrst-line treatment in wild-type
melanomas [1]. Temozolomide is a chemically related oral
drug and therefore convenient for outpatient therapy. It
demonstrated efﬁcacy equal to that of DTIC in two phase 3
trials [2] although the difference in overall survival,
progression-free survival or overall response rate was not seen
between the two arms, despite dose intensiﬁcation in the
EORTC trial [2]. Temozolomide penetrates into the central
nervous system (CNS) and may induce regression of CNS
metastases. Polychemotherapy containing cisplatin, vindesine
and DTIC or the combination of carboplatin and paclitaxel [3]
may produce responses in 20–40% of the patients. However, an
impact on disease-free or overall survival was never shown in
randomized trials, considering that these therapies have
substantial persisting toxic effects.
Biochemotherapy, a combination of interleukin-2 (IL-2)
and/or interferon-α (IFN-α) with chemotherapeutic agents
such as DTIC, cisplatin and vinblastine, has demonstrated a
high response rate although it was not translated into improved
survival and was associated with an increase in toxicity [4, 5].
molecular dissection of melanoma
In the last decade, melanoma was dissected into several
molecular subgroups based on genomic alterations including
mutations, deletions and ampliﬁcations in addition to clinical
features. Up to 50% of melanomas derived from skin without
chronic sun damage (intermittently exposed to UV) contain
mutations in the gene encoding the serine–threonine protein
kinase v-raf murine sarcoma viral oncogene homolog B1
(BRAF). BRAF together with ARAF and CRAF activate a
second protein known as mitogen-activated protein kinase
kinase (MEK), which in turn activates extracellular signal-
regulated kinase (ERK). Additionally, 20% of melanomas
present RAS (rat sarcoma) mutations. Finally, a minor
percentages have activating mutations in the KIT gene, which
are most common in mucosal melanomas derived from the
genital regions [6, 7], or mutations in GNA11/ or GNAQ
genes in uveal melanomas [8, 9]. Some of the targetable
mutations in KIT gene are also found in acral and other
mucosal melanomas but with lower frequency. The KIT
receptor protein tyrosine kinase is a transmembrane protein
consisting of extracellular and intracellular domains. Most KIT
mutations are localized to exon 11, which codes for the
juxtamembrane domain and exon 13, which codes for a kinase
domain.
breakthrough with kinase inhibitor
therapy in melanoma subgroups
The best-validated targeted therapies in melanoma are the
selective BRAF inhibitors, vemurafenib (PLX4032, Zelboraf™)
and dabrafenib (GSK2118436). Both are relatively selective for
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their intended target, V600E BRAF, with little cross-reactivity
for wild-type BRAF and CRAF [10, 11]. Few other kinases are
inhibited with 10- to 100-folds of the concentration needed to
inhibit V600E BRAF. These agents inhibit selectively the
growth of cells that harbor a V600E BRAF mutation. In several
clinical trials, vemurafenib and dabrafenib have both
demonstrated impressive clinical efﬁcacy with the response rate
in the range of 50% in V600E-mutated advanced melanomas
[11–13].
Unfortunately, the response duration is highly variable as
shown by phase 2 and phase 3 trials. In a phase 2 trial,
vemurafenib produced objective responses in 53% of 132
patients with metastatic melanoma harbouring a V600E or
V600K mutation [14]. The median duration of response was
6.7 months. In a phase 3 trial, with dacarbazine monotherapy
as the control arm, overall survival was signiﬁcantly improved
among the 337 patients with V600E mutant metastatic
melanoma compared with the 338 patients who received
dacarbazine (hazard ratio 0.37; 95% CI, 0.26 to 0.55; P < 0.001)
[15], as was the progression-free survival. In addition, the
response rate was much better in the vemurafenib arm (48%
objective response rate versus 5%; P < 0.001). These data led to
the approval of vemurafenib in the United States, European
community and Switzerland.
The appearance of acanthopapillomas, keratoacanthomas
and cutaneous squamous cell carcinomas early in the course of
treatment with these kinase inhibitors needs special attention
[16, 17]. Furthermore, there are well-documented cases of new
primary melanomas that do not present a BRAf V600
mutation [14, 18]. Other more common toxic effects observed
with vemurafenib include arthralgia, photosensitivity [14], rash
and fatigue. Generally, these toxic effects are mild to moderate
in severity and, when severe, can be managed with dose
interruption and/or reduction. The most common toxic effects
observed with dabrafenib are comparable, except there is no
photosensitivity [11].
Multiple in vitro studies have demonstrated that mutated
BRAF signaling is mediated via MEK and ERK [19]. Thus,
selective MEK inhibitors have shown efﬁcacy in patients with
BRAF mutant metastatic melanoma. Selumetinib was the ﬁrst
allosteric, selective MEK inhibitor to be evaluated in a phase 2
clinical trial in patients with metastatic melanoma [20]. This
agent produced an objective response rate in patients with
BRAF mutant tumors but not in wild-type tumors and thus
reinforcing the importance of selecting a speciﬁc patient
populations. In the phase 1 dose escalation clinical trial,
GSK1120212 demonstrated an objective response rate of 44%
with a median progression-free survival of 7.4 months in
patients with BRAF mutant melanoma [21]. This agent is
being evaluated in additional phase 2 and phase 3 trials in
BRAF mutant melanoma. Other MEK inhibitors are currently
investigated in NRAS-mutated melanomas with some
promising results. The combination of kinase inhibitors such
as concomitant BRAF and MEK inhibitor therapy is deﬁnitely
a key to the future of development strategies.
The kinase inhibitor imatinib has proven efﬁcacy in patients
with advanced melanoma harboring KIT mutations [22]. KIT
mutations are found in low frequency (10% or less) in
melanomas arising from a mucosal or acral lentiginous
surfaces [23]. As the vast majority of patients with metastatic
melanoma suffer from primary tumors on glabrous skin
(trunk, extremities and head/neck), the number of patients in
the metastatic setting with mutated KIT is small. Durable
responses were observed in 16% of a 51 patient cohort with
either mutations in KIT or ampliﬁcation [24]. In a phase 2 trial
in which 43 patients with KIT mutations or ampliﬁcation were
enrolled, 23% of patients had objective responses [25]. In both
studies, certain mutations in exons 11 and 13 of v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog
(particularly the L576P mutation in exon 11) were associated
with the highest response rate. Thus, it appears that sensitivity
to KIT inhibition exists in metastatic melanoma [20] but it is
conﬁned to a subset of this already small subpopulation of
patients.
After decades of standstill, progress in understanding the
biology of melanomas has resulted in powerful targeted
therapies with impact on progression-free and overall survival.
Ongoing research is focussed on resistance mechanisms and
strategies to overcome them [26]. In order to further improve
the outcome in this still poor prognosis population, patients
should be encouraged to participate in well-designed clinical
trials.
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